The Global Health Body Raises Alert Over Severe Shortage of Weight-Loss Jabs
Less than a tenth of individuals that would benefit from GLP-1 drugs such as Wegovy are able to get them, caution the WHO as it publishes its first recommendations on the drugs.
Considering more than one billion people worldwide currently obese, it is calling for increased and just availability to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a chronic disease that can be managed with thorough and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are key obstacles to universal access to the jabs that can aid individuals in losing substantial body mass, explains the organization.
Weight-Loss Drug Supply Crisis
Despite the present best projected case, the production of these medications might only reach about 100 million people – less than 10% of the global need, according to the health organization.
The recommendation urges governments and firms to widen access, by approaches like licensing agreements.
Exclusive production rights on semaglutide – the core ingredient of a leading brand – is due to expire in a number of nations in 2026.
How Weight-Loss Jabs Operate
The injections mimick a body's own hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so users eat less.
Patients typically start to lose weight in the initial weeks of beginning the regular doses.
Evidence indicates users may regain a significant portion within a year of stopping the drug, when their typical hunger return.
Being above a healthy weight elevates your likelihood for experiencing diseases, like type 2 diabetes, heart disease, brain attack, and some malignancies.
Obesity affects people in every country and was associated with 3.7 million fatalities worldwide in 2024, according to the health agency.
